| OIPE   |  |                                |                      |                      |                                   |          |  |
|--|--|--------------------------------|----------------------|----------------------|-----------------------------------|----------|--|
|  | N 1 5 2006 Under the reference Reduction Act of 1995, no personal research and the research | مري•<br>ons are required to re | U.S<br>spond to a c  | . Patent and Tradema | ed for use through 07/31/2006. OM | COMMERCE |  |
| PETHICALE RESTENSION OF TIME UNDER 37 CFR 1.136(a)   |  |                                |                      | Docket Number        | (Optional)                        |          |  |
| FY 2005  |  |                                |                      | 029065.48666C1       |                                   |          |  |
| (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)  |  |                                | First Named Inventor |                      |                                   |          |  |
|  |  |                                | Marc G. ACHEN        |                      |                                   |          |  |
| Application Number 10/627,631  |  |                                | Filed July 2         | 28, 2003             |                                   |          |  |
| For Methods for Treating Neoplastic Disease Characterized by Vascular Endothelial Growth Factor D Expression, for Screening for Neoplastic Disease or Metastatic Risk, and for Maintaining Vascularization |  |                                |                      |                      |                                   |          |  |
| Art Unit 1644  |  |                                | Examiner P. N. Huynh |                      |                                   |          |  |
| This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.   |  |                                |                      |                      |                                   |          |  |
| The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):  |  |                                |                      |                      |                                   |          |  |
|  |  | <u>Fee</u>                     | <u> </u>             | Small Entity Fee     |                                   |          |  |
|  | One month (37 CFR 1.17(a)(1))  | \$120                          |                      | \$60                 | \$                                | _        |  |
| · 🗆 1  | wo months (37 CFR 1.17(a)(2))  | \$450                          |                      | \$225                | \$                                | _        |  |
| . 🛛 1  | Three months (37 CFR 1.17(a)(3))   | \$1020                         |                      | \$510                | \$_1020.00                        | _        |  |
| □ F  | Four months (37 CFR 1.17(a)(4))  | \$1590                         |                      | \$795                | \$                                | _        |  |
| □ F  | Five months (37 CFR 1.17(a)(5))  | \$2160                         |                      | \$1080               | \$                                | _        |  |
| ☐ Appl   | icant claims small entity status. See 37 CFF   | R 1.27.                        |                      |                      |                                   |          |  |

| ☐ Payment by credit card. Form PTO-2038 is attached.  |
|---|
| ☐ The Director has already been authorized to charge fees in this application to a Deposit Account.                         |
| ☑ The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account |

Number 05-1323 (Docket No. 029065.48666C1). I have enclosed a duplicate copy of this sheet. WARNING: Information on this form may become public. Credit card information should not be included on this form.

Provide credit card information and authorization on PTO-2038.

| assignee of record of the entire interest. See 37 CFR<br>Statement under 37 CFR 3.73(b) is enclosed (Form P |                                     |
|---|-------------------------------------|
|   | 269 / 50,210                        |
| attorney or agent under 37 CFR 1.34.  Registration number if acting under 37 CFR 1.34                       |                                     |
| The   | June 15, 2006                       |
| Signature   | 96/16/2096 JAPONE 80800013 18627631 |
| J. D. Evans / Thomas M. Haas  | (202) 624-2500 1929.99 OP           |
| Typed Or Printed Name   | 01 FC:188ephone Number              |

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

2 forms are submitted.

☐ A check in the amount of the fee is enclosed.

the applicant/inventor.

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents**, P.O. Box 1450, Alexandria, VA 22313-1450.